Back to today’s briefing

Story perspectives

Breakthrough Gene Therapy Restores Hearing in Children

10/16/2025

49 6 Full Breakdown

Summary

Story summary

In the CHORD study, 11 of 12 treated children showed significant hearing improvements after the DB-OTO gene therapy, with three achieving normal hearing.
Benefits were observed in participants up to 16 years old when the therapy was delivered by a single infusion.
Ongoing assessments are planned for up to five years to evaluate durability.
The development marks a step toward addressing congenital profound hearing loss caused by OTOF variants.

1 of 1

Story summary

In the CHORD study, 11 of 12 treated children showed significant hearing improvements after the DB-OTO gene therapy, with three achieving normal hearing.
Benefits were observed in participants up to 16 years old when the therapy was delivered by a single infusion.
Ongoing assessments are planned for up to five years to evaluate durability.
The development marks a step toward addressing congenital profound hearing loss caused by OTOF variants.